Phase 2
Completed N=233
A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
Lipoprotein Disorder
Source: ClinicalTrials.gov NCT05563246 ↗
Enrolled (actual)
233
Serious AEs
4.3%
Results posted
Mar 2025
Primary outcomePrimary: Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay — -47.35; -81.57; -85.71; 0.48 Percent change — p=<.001
Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3473329 in adult participants with elevated Lp(a) at high risk for cardiovascular events.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change From Baseline in Lp(a) - Assessed Via Intact Lp(a) Assay |
-47.35; -81.57; -85.71; 0.48 | <.001 sig |
| PRIMARY Percent Change From Baseline in Lp(a) - Assessed Via Apo(a) Assay |
-42.26; -70.90; -69.88; -3.15 | <.001 sig |
| SECONDARY Percentage of Participants Who Achieved Lp(a) < 125 Nmol/L - Assessed Via Intact Lp(a) Assay |
69.6; 95.6; 95.7; 6.1 | <.001 sig |
| SECONDARY Percentage of Participants Who Achieved Lp(a) < 125 Nmol/L - Assessed Via Apo(a) Assay |
37.9; 82.1; 77.2; 3.3 | <.001 sig |
| SECONDARY Percent Change From Baseline in Apolipoprotein B (ApoB) |
-10.49; -14.53; -17.56; -1.70 | 0.110 |
| SECONDARY Percent Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) |
21.87; -2.41; -15.39; -9.91 | 0.131 |
| SECONDARY Pharmacokinetics (PK): Trough Concentrations (C-trough) of LY3473329 |
13.0; 42.4; 83.3; 14.8; 39.3; 77.9 | — |
Eligibility Criteria
Inclusion Criteria
- Participants must be at least 40 years old
- Participants with Lp(a) ≥175 nmol/L at randomization, measured at the central laboratory.
- High risk for cardiovascular events defined as documented coronary artery disease (CAD), stroke, or peripheral artery disease or atherosclerotic cardiovascular disease (ASCVD) risk equivalents (familial hypercholesterolemia or type 2 diabetes).
- Participants on the following medications according to local practice must be on a stable regimen for at least 4 weeks prior to randomization and expected to remain on a stable regimen through the end of the post-treatment follow-up period.
- lipid-lowering drugs
- testosterone, estrogens, anti-estrogens, progestins, selective estrogen receptor modulators, or growth hormone
- Have a body mass index within the range 18.5 to 40 kilogram/square meter (kg/m²), inclusive.
- Males who agree to use highly effective or effective methods of contraception may participate in this trial.
- Women of childbearing potential (WOCBP) who agree to use highly effective or effective methods of contraception and women not of childbearing potential (WNOCBP) may participate in this trial.
Exclusion Criteria
- Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition that, in the opinion of the investigator, would potentially affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data.
- Any of the following, or other events indicating unstable medical condition in the opinion of the investigator, within 3 months of randomization:
- major surgery
- coronary, carotid, or peripheral arterial revascularization
- stroke or transient ischemic attack
- myocardial infarction or unstable angina
- acute limb ischemia
- Have, in the 6 months prior to day 1, uncontrolled Type 1 or Type 2 diabetes
- Have uncontrolled hypertension
Data sourced from ClinicalTrials.gov (NCT05563246). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.